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2A genome-wide association study (GWAS) for open angle glaucoma (OAG) blindness was 
conducted using a discovery cohort of 590 cases with severe visual field loss and 3956 controls. 
Genome-wide significant associations were identified at TMCO1 (rs4656461 (G) OR=1.68, 
p=6.1x10-10) and CDKN2B-AS1 (rs4977756 (A) OR = 1.50, p=4.7x10-9). These findings were 
replicated in a second cohort of advanced OAG cases (rs4656461 p=0.010; rs4977756 p=0.042) 
and two further cohorts of less severe OAG. The study wide odds ratios are 1.51 (1.35-1.68), 
p=6.00x10-14 at TMCO1, and 1.39 (1.28-1.51), p=1.35x10-14 at CDKN2B-AS1 (also known as 
CDKN2BAS and ANRIL). Carriers of 1 or more risk alleles at both loci concurrently are at >3-
fold increased risk of glaucoma. We demonstrate retinal expression of genes at both loci, and 
show that CDKN2A and CDKN2B are strongly upregulated in an animal model of glaucoma.  
Glaucoma is a group of neurodegenerative ocular diseases united by a clinically characteristic optic 
neuropathy. It is the second leading cause of blindness worldwide1. Primary open angle glaucoma 
(OAG) is the commonest subtype1. OAG pathogenesis and factors determining disease progression 
are poorly understood. Early intervention with measures to reduce intraocular pressure retards 
visual loss in most individuals2, but many cases of glaucoma remain undiagnosed until irreversible 
vision loss has occurred. Elucidation of SNPs associated with severe outcomes could enable better 
targeting of treatments which carry cost and morbidity, to individuals at highest risk of blindness. 
Linkage and candidate gene studies have identified several genes likely to be involved in OAG 
including myocilin3 and NTF44, although for the latter, findings have varied in different 
populations5. A recent GWAS using Icelandic OAG cases of unselected severity identified 
association with variants near CAV16. To identify genes predisposing individuals to OAG blindness, 
we performed a GWAS in Australian Caucasians with advanced OAG (individuals with OAG who 
have progressed to severe visual field loss or blindness). 
Advanced OAG cases (N=590 after data cleaning) were selected from the Australian & New 
Zealand Registry of Advanced Glaucoma (ANZRAG) and the Glaucoma Inheritance Study in 
Tasmania (GIST)7,8. Two previously described Australian samples were used as controls (N=1801 
and 2155, total 3956)9. Cohort demographics are given in Table 1 and recruitment and disease 
definitions are in the Supplementary Material. Samples were typed on Illumina arrays (Cases: 
Omni1; Controls: HumanHap610 or HumanHap660). Cases and controls were combined into a 
single data set for cleaning and imputation. All participants were Australian Caucasians of European 
descent. 
After cleaning, 298,778 SNPs were available for association testing. The genomic inflation factor 
(λ) in the discovery cohort was 1.06 (Q-Q plots uncorrected and corrected for λ are in 
Supplementary Fig. 1A and B). The λ reduced to 1.04 when the first 10 principal components were 
included as covariates. The association results across the genome are displayed in Figure 1; results 
are presented corrected for λ=1.06, without correction for principal components. Results with 
correction for principal components were similar (data not shown). Two regions clearly reached 
genome-wide significance (defined at p<5x10-8, Table 2), with p=6.1x10-10 at rs4656461 (G) near 
the TMCO1 gene on chromosome 1q24, and p=4.7x10-9 at rs4977756 (A) in the CDKN2B-AS1 gene 
on chromosome 9p21. Association results at these loci for both genotyped and imputed SNPs are 
shown in Figure 2. Imputation of SNPs from the 1000 Genomes project did not reveal any SNPs 
with substantially stronger association than the top genotyped SNPs (Fig. 2), or identify additional 
genome-wide significant loci. At both loci, the most associated SNP is supported by concordant 
results for other SNPs in moderate or high linkage disequilibrium.  
Three replication cohorts were drawn from the Australian Caucasian population and are all of 
European descent (Table 1). The advanced glaucoma replication cohort consisted of 334 additional 
advanced OAG cases with 434 elderly controls. The less severe cohort consisted of 465 OAG cases 
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and 1436 controls from the Wellcome Trust Case-Control Cohort 1958 Birth Cohort (WTCCC 
58BC). The third cohort was a population based study, the Blue Mountains Eye Study, containing 
93 cases of glaucoma and 2712 examined elderly controls. The most associated SNPs at each locus 
clearly replicated in all cohorts (Table 2). Other SNPs in both of these regions were also associated 
in the replication cohorts (Supplementary Table 1A). Combining all replication cohorts gave an 
odds ratio (OR) of 1.39 (95% CI, 1.20-1.61), p=7.56x10-6 for rs4656461 near the TMCO1 gene and 
1.33 (1.19-1.48), p=4.19x10-7 at rs4977756 in the CDKN2B-AS1 gene (Supplementary Table 1B). 
All SNPs of interest are also still significantly associated following adjustments for age and sex in a 
logistic regression, indicating that the observed associations are independent of these parameters, 
despite the differences between case and control cohorts. We combined all available controls to 
enable a comparison of odds ratios for the risk alleles at both loci between the advanced OAG 
cohorts and the less severe OAG cases (Supplementary Table 1C). Stronger ORs were observed in 
the advanced cases, and these results support the hypothesis that the risk alleles identified are 
associated with all OAG, but are more strongly associated with cases which progress to advanced 
disease. Alternatively, higher diagnostic certainty in severe disease could account for this 
observation. 
 
Combined analysis of discovery and all replication cohorts generated an overall OR 1.51 (1.35-
1.68), p=6.0x10-14 for rs4656461, and 1.39 (1.28-1.51), p=1.35x10-14 for rs4977756.  Haplotype 
analyses indicate three common haplotypes around TMCO1 and two at CDKN2B-AS1. The overall 
p-value for association is 6.56x10-12 around the TMCO1 gene and 2.59x10-9 at the CDKN2B-AS1 
locus (Supplementary Table 2). In both cases the risk alleles detected in the single SNP analysis are 
present on a single common haplotype which shows significant association. The haplotype with the 
alternative allele at each location appears to be protective against OAG development. Twelve OAG 
patients homozygous for the risk allele at rs4656461 were sequenced at all coding exons of the gene 
and the 3’UTR. Several common SNPs in the 3’UTR were found to be present on the risk haplotype 
although the functionality of these SNPs is not known (Supplementary Table 3). The lack of 
identified coding variants suggests the true causative variants are likely to be located in a regulatory 
region of TMCO1. 
 
To obtain an unbiased estimate of risk for advanced glaucoma, we focused on the first replication 
cohort10. Taking these advanced glaucoma cases (N=334), the matched examined elderly controls 
(N=434), and similar age-matched controls from the BMES cohort (N=502), we fitted rs4977756 
and rs4656461 in a logistic regression. Assuming an additive model, individuals carrying four risk 
alleles (two at each locus) had 4.50 (95% CI=1.84-11.01) fold higher risk of advanced OAG relative 
to non-carriers. Grouping individuals with one or two risk alleles together at both loci (dominant 
model), gave a 3.03 (95% CI=1.52-6.07) fold increased risk. Eighteen percent of the normal 
population are in this risk category.  
 
Two control cohorts were used in this study; one a population sample based on parents of twins and 
the other a sample of endometriosis cases. Cases and controls were subjected to the same cleaning 
regime to ensure a well matched dataset. The male:female ratio was similar between the case cohort 
and the twin-based controls, but the endometriosis 'controls' were all female. We repeated the 
analysis excluding the endometriosis controls. The p-values at rs4656461 and rs4977756 changed to 
p=5.3x10-9 and p=1.1x10-7, respectively, with the reduced significance due to smaller sample size as 
allele frequencies are very similar between control cohorts (Supplementary Table 4A). X 
chromosome results were also similar. In addition, we utilised the Wellcome Trust Case-Control 
Cohort 1958 Birth Cohort (WTCCC 58BC) data as an alternative control cohort. Both loci reached 
genome-wide significance in this analysis, indicating that our findings do not represent an artefact 
of the historic controls utilised (Supplementary Table 4B, Supplementary Fig. 1C). 
 
SNP rs4656461 at the 1q24 locus is ~6.5 kb downstream of the TMCO1 gene. SNP rs4977756 at the 
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9p21 locus is located within the antisense RNA gene CDKN2B-AS1. This region also harbors the 
tumour suppressor genes CDKN2A and CDKN2B and is adjacent to the MTAP gene. CDKN2A also 
encodes an alternate open reading frame, ARF. We analysed expression of these genes in human 
ocular tissues by RT-PCR. All the genes are expressed in the iris, ciliary body, retina and optic 
nerve, but the expression levels varied among the analysed tissues (Fig. 3A). Furthermore, we 
determined which of the CDKN2B-AS1 splice variants were expressed in the retina, the tissue 
ultimately compromised in glaucoma. RT-PCR revealed expression of three splice variants of this 
gene in the human retina (Fig. 3B). This is consistent with expression of more than one CDKN2B-
AS1 splice variants in a tissue or cell line11,12. We utilized well characterized antibodies directed 
against CDKN2A, CDKN2B, MTAP and TMCO1 to explore the distribution of these proteins in rat 
retina. CDKN2A and CDKN2B were expressed in retinal ganglion cells (RGC) and other retinal 
cell types displaying nuclear patterns of localization, similar to those reported in other tissues 
(Supplementary Fig. 2). TMCO1 was also associated with all retinal cells, but strongest expression 
was observed in RGC. MTAP was expressed at low levels in retinal astrocytes (data not shown). To 
ascertain whether these genes are candidates for involvement in the pathogenesis of glaucoma, we 
performed real-time PCR analysis of their expression levels in a validated rat model of glaucoma 13 
(Fig. 4). Strong upregulation of expression of Cdkn2a and Cdkn2b, but not Tmco1 was observed in 
the retina one week after induction of ocular hypertension, a time-point corresponding to ongoing 
RGC death, as indicated by axonal cytoskeleton damage in the optic nerve of the animals studied. 
 
Recessive mutations in TMCO1 cause a syndrome consisting of craniofacial dysmorphism, skeletal 
anomalies and mental retardation14.  The gene encodes a transmembrane protein with a coiled-coil 
domain that may localise to the Golgi apparatus and endoplasmic reticulum15 or to the 
mitochondria16 in different cell types. In humans, the gene is ubiquitously expressed in developing 
and adult tissues14. The protein sequence is completely conserved among many mammalian 
species14.  Although requiring experimental confirmation, Zhang et al proposed a role for TMCO1 
in apoptosis16. This may suggest a mechanism for the association with glaucoma, which is 
characterised by excessive RGC apoptosis. It is also possible that other genes adjacent to TMCO1 
such as ALDH9A1 could be responsible for the glaucoma association observed in this study.  
 
CDKN2B-AS1 resides in the 9p21 region that has been clearly associated with cardiovascular 
disease 17, diabetes18, intracranial aneurysm19 and glioma20. The antisense RNA encoded by 
CDKN2B-AS1 regulates neighbouring genes at 9p21, particularly CDKN2B with which its 
expression levels are reciprocally related21. CDKN2B and CDKN2A activate the retinoblastoma 
tumour suppressor pathway, whereas ARF activates the p53 tumour suppressor pathway. The 9p21 
locus is activated in response to oncogenic stimuli22. The CAV1 gene, recently reported to be 
associated with OAG6, regulates mitogenic signalling and acts synergistically with CDKN2A23. 
Although the CAV1 SNP (rs4236601) did not reach statistical significance in this GWAS (p=0.17 
for a 1 sided test), the observed odds ratio of 1.07 is consistent with that previously reported in 
larger European cohorts, as are the allele frequencies (cases; 0.290, controls; 0.276 for A allele). It 
should be noted that many of the cases in the current study are included in the previously reported 
Australian replication cohort6. Genes at the 9p21 locus are known to play a role in aberrant cell 
division, and we propose that the 9p21 OAG risk variants may predispose RGCs to gradual 
apoptosis. This hypothesis is supported by observations that the opposite risk alleles in CDKN2B-
AS1 are associated with glaucoma and glioma. For example, at rs4977756 and rs1063192, the G and 
C alleles respectively, are protective for glaucoma but are the risk alleles for glioma20. The direction 
of association is the same for glaucoma as for cardiovascular disease17 and diabetes18, but further 
work is required to determine whether the same causative variant/s underlie these different disease 
associations. 
 
Recently, rs1063192 in CDKN2B was reported to be associated at genome-wide significance with 
optic cup-to-disc ratio in normal individuals24.  Nominal association of this SNP with glaucoma in a 
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small case series was also reported24. In our study, this particular SNP had a p-value of 3.9x10-7 in 
the discovery cohort and the nearby SNPs in CDKN2B-AS1 reached genome-wide significance. 
Thus, we provide further compelling evidence that the 9p21 region is a strong genetic risk factor for 
OAG in support of the previous suggestive association with OAG at this locus. 
 
 
This study shows clear evidence of association of two genes, TMCO1 and CDKN2B-AS1 with 
advanced OAG, imparting a 3 fold increase in risk for carriers of one or more risk alleles at the two 
loci. In addition, we have shown strong upregulation of CDKN2A and CDKN2B in response to 
elevated intraocular pressure, further indicating that this region is important in the molecular 
pathways leading to glaucoma development. This discovery was made utilising a novel approach of 
selecting cases with severe blinding OAG for the GWAS, but as expected the risk alleles are also 
associated with less severe cases, demonstrating the efficacy of using extreme cases to identify 
genes for a common disease. OAG can be difficult to diagnose in the early stages, and these 
findings may be useful in the future to prioritise treatment effectively for glaucoma suspects in 
whom it is often difficult to decide upon timing of treatment initiation. As treatment for glaucoma is 
proven to slow disease progression2, timely initiation of conventional treatment in those at highest 
risk could reduce glaucoma blindness. In addition, we have begun to elucidate novel biochemical 
pathways involved in this disease, which could lead to more targeted OAG treatment regimes 
aiming to protect RGC in ways other than lowering intraocular pressure which has hitherto formed 
the cornerstone of treatment. 
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Figure legends 
 
Figure 1: Association results for genotyped SNPs. SNPs with p-value reaching genome-wide 
significance (p<5x10-8) are shown in black. Results are corrected for λ=1.06. Chromosome 23 
refers to the X chromosome.  
 
 
Figure 2: Association results for SNPs at the genome-wide significant loci, corrected for lambda of 
1.06. Genotyped SNPs are indicated by solid triangles and imputed SNPs by hollow circles. The top 
ranked SNP at each locus is shown as a solid diamond. Imputation p-values for all SNPs are plotted. 
Color scheme indicates linkage disequilibrium between top ranked SNP and other SNPs in the 
region. Note imputed and genotyped p-values for genotyped SNPs differ slightly because for the 
imputed result, analysis is based on dosage scores whereas with genotyped SNPs hard genotype 
calls are used. A) chromosome 1q24 region. Imputation p-value was p=1.0x10-9 for top SNP 
rs7524755, with the top genotyped SNP, rs4656461 the fourth best SNP after imputation, p=1.6x10-
9 . B) chromosome 9p21 region. Imputation p-value was p=3.7x10-9 for top SNP rs10757270, with 
top genotyped SNP, rs4977756 the second best SNP after imputation, p=8.1x10-9.  
 
 
Figure 3: Ocular expression of the genes at the glaucoma associated loci. A) Expression of the 
TMCO1, CDKN2A/ARF, CDKN2B, CDKN2B-AS1 and MTAP genes was analyzed in various human 
eye tissues by RT-PCR using gene-specific primers (Supplementary Table 5). GAPDH was 
amplified to control for the amount of cDNA template used from each tissue for PCR. The expected 
size of each PCR product is indicated in Supplementary Table 5B) Expression of CDKN2B-AS1 
splice variants in human retina. RT-PCR was performed with gene-specific primers in exon 1 and 
19 of the CDKN2B-AS1 gene (Supplementary Table 5C). Lanes 1, 2 and 3 correspond to the splice-
variants amplified upon primer annealing at 52°C, 54°C and 56°C respectively. The variant in lane 
1 results from splicing of exons 1-5-6-7-19, in lane 2 from splicing of exons 1-5-6-7-10-11-13-14-
15-16-17-18-19 and in lane 3 from splicing of exons 1-5-6-7-15-16-17-18-19. These variants are 
different to previously reported CDKN2B-AS1 variants 11,12. The full-length variant (DQ485453) 
and alternatively spliced variants (DQ485454 and GQ495924) 11,12 were undetectable in human 
retina (data not shown). M, molecular weight markers in basepairs; RT-, reverse transcription 
negative control; -ve C, PCR negative control. 
 
 
Figure 4:  (A) Expression of Tmco1 Cdkn2a and Cdkn2b mRNAs in rat retina 7 days after 
induction of experimental glaucoma (mean intraocular pressure at time of death of 32±3.7 mmHg) 
as determined by quantitative real-time RT-PCR, where n=4. Error bars indicate standard error of 
the mean. (B) Axonal degeneration in the distal optic nerve of one representative animal, as 
evaluated by immunolabelling for non-phosphorylated neurofilament heavy protein. Numerous 
axonal swellings and abnormalities are visible in the optic nerve of the treated eye compared with 
the control optic nerve, which appears normal. Scale bar panels B-C: 25 μm. 
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Tables 
 
 
Table 1: Demographic features of the cohorts. 
 
 n  age  % female 
Cohort Case Control  Case Control p-value  Case Control p-value 
Discovery 615 3956 
 
76.6±13.9 43.4±11.5 <1.0x10-6 
 
52.1 78.9* <1.0x10-6 
Advanced 
replication 334 434 
 
74.9±11.7 78.7±9.1 2.0x10-6 
 
55.6 59.1 0.35 
Less Severe 
replication 465 1436 
 
71.8±12.6 52.0±0 <1.0x10-6 
 
61.4 49.7 1.2x10-5 
Blue 
Mountains 
Eye Study 
93 2712 
 
76.5±9.4 70.1±10.1 <1.0x10-6 
 
8.5 45.4 <1.0x10-6 
Combined 
replication 892 4582 
 
72.0±13.0 64.9±12.4 <1.0x10-6 
 
51.1 47.4 0.050 
* one of the two control cohorts was entirely female, discussed in main text. 
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Table 2: Association results for genome-wide significant genotyped SNPs in the discovery cohort and three replication cohorts. The frequency of the risk 
allele in cases and controls is given. All tests were performed under an allelic model. 
 
 
 
   Discovery Cohort Advanced glaucoma replication Less severe glaucoma replication Blue Mountains Eye Study 
SNP:Risk 
allele Chr 
Build 36 
position 
Frequency 
case/control 
P- 
value* 
OR (95% 
CI) 
Frequency 
case/control
P-
value 
OR  
(95% CI) 
Frequency 
case/control
P-
value 
OR  
(95% CI) 
Frequency 
case/control
P-
value 
OR  
(95% CI) 
rs4656461:G 1 163953829 0.19/0.12 6.1x10-10 
1.68 
(1.43-1.98) 0.17/0.12 0.010 
1.47 
(1.09-1.97) 0.15/0.12 0.026 
1.28 
(1.03-1.59) 0.17/0.12 0.022 
1.57 
(1.07-2.32) 
rs7518099:C 1 164003504 0.18/0.12 4.7x10-10 
1.67 
(1.42-1.96) 0.16/0.12 0.032 
1.38 
(1.03-1.86) 0.15/0.12 0.022 
1.29 
(1.04-1.61) 0.18/0.12 0.007 
1.68 
(1.15-2.46) 
rs4977756:A 9 22058652 0.69/0.60 4.7x10-09 
1.50 
(1.31-1.70) 0.69/0.63 0.042 
1.25 
(1.01-1.56) 0.64/0.58 0.013 
1.21 
(1.04-1.41) 0.68/0.60 0.015 
1.48 
(1.08-2.04) 
rs10120688:A 9 22046499 0.58/0.48 1.4x10-08 
1.44 
(1.28-1.63) 0.56/0.52 0.153 
1.16 
(0.95-1.43) 0.51/0.46 0.003 
1.27 
(1.08-1.48) 0.57/0.48 0.025 
1.40 
(1.04-1.88) 
* corrected for lambda of 1.06 
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ONLINE MATERIALS & METHODS: 
Participant Recruitment: 
See Supplementary Note online. 
 
Genotyping and data quality control: 
Following DNA extraction Australian twin and endometriosis sample controls were genotyped at 
deCODE Genetics (Reykjavik, Iceland) on Illumina HumanHap 610W Quad and Illumina 
Human670Quad Beadarrays, respectively. Cases were genotyped in the laboratory of MAB, on 
Illumina Human1M-Omni arrays. SNPs with a mean BeadStudio GenCall score <0.7 were excluded 
from the controls. All samples had successful genotypes for >95% of SNPs. SNPs with call rates 
either <0.95 (minor allele frequency, MAF > 0.05) or <0.99 (MAF > 0.01), Hardy-Weinberg 
equilibrium in controls P<10-6, and/or MAF <0.01 were excluded. Cryptic relatedness was 
identified through the production of a full identity by state matrix and 0 cases and 72 controls were 
removed. Ancestry outliers were identified by principal component (PC) analysis, using data from 
11 populations of the HapMap 3 and five Northern European populations genotyped by the 
GenomeEUtwin consortium, using the EIGENSOFT package25 using a subset of 160,000 
independent SNPs. Individuals (n=25 cases and 219 controls) lying ≥ 2 standard deviations from the 
mean PC1 and PC2 scores were removed30. Following these exclusions there were 590 cases, 
genotyped for 790,038 SNPs and 3,956 controls, genotyped for 518,687 SNPs. Our primary 
analysis was based on a common set of 298,778 SNPs. To investigate population stratification in the 
cleaned data set, we generated Q-Q plots. These same SNPs were used to generate the first 10 
principal components for case and control samples combined using EIGENSOFT.  
 
Genomic imputation: 
Imputation for the Australian twins was performed using MACH2 with data obtained by the Centre 
d'Etude du Polymorphisme Humain from the 1000 Genomes reference panel 2010_03 release. 
Imputation was based on a set of autosomal SNPs common to all samples (n=292,883). The total 
number of SNPs imputed with imputation r2>0.5 was 5,548,553 and these were taken forward for 
analysis. 
 
Association analysis: 
Association analysis was performed using PLINK26. Dosage scores from imputation analysis was 
performed using MACH2DAT27. Analysis was conducted with and without the first 10 principal 
components included as covariates (with negligible difference to results, data not shown). Figure 2 
was prepared using LocusZoom28.  
 
Replication study genotyping and analysis 
All genome-wide significant SNPs were further examined in an independent replication, along with 
additional SNPs at each locus. SNPs chosen for genotyping were those mapping to each locus 
defined as within annotated genes TMCO1 (4 SNPs), CDKN2A (2 SNPs), CDKN2B (2 SNPs) or 
CDKN2B-AS1 (5 SNPS) and ranked within the top 1000 genotyped SNPs. In addition, SNPs 
previously reported as associated with other phenotypes at the 9p21 locus but not typed in the 
discovery phase were also included if the assay design allowed them to multiplex with the other 
SNPs (4 SNPs). SNPs were genotyped using iPLEX Gold chemistry (Sequenom Inc, San Diego, 
CA, USA) in a single plex on an Autoflex Mass Spectrometer (Sequenom Inc.) at the Australian 
Genome Research Facility (Brisbane, Australia). Genotypes for controls from the BMES cohort 
were extracted from a previously conducted genome-wide association scan using Illumina 
HumanHap 670 arrays. Genotypes of the WTCCC 58BC cohort typed on the Illumina 
HumanHap550 array were downloaded from the European Genome-phenome Archive and the 
relevant SNPs extracted. Each SNP in the replication phase was checked for consistent strand and 
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flipped in one dataset if necessary. Association analysis was conducted in PLINK.  Advanced 
replication cases were compared to 434 elderly examined controls. 465 less severe cases were 
compared to the WTCCC 58BC data (n=1436) and glaucoma cases from within the BMES (n=93) 
was analysed compared to all other participants with available genotype data (n=2712). Data were 
pooled for the combined replication cohort analyses. Age and sex were included in a logistic 
regression under an additive model. 
 
Haplotype analysis: 
The haplotype analysis was conducted on the combined dataset of all cases, the discovery controls 
and a subset of BMES controls that were genotyped in house. Analysis was conducted in PLINK. 
All four TMCO1 SNPs from the replication phase were included in the haplotype. Prior to analysis, 
the chromosome 9 locus was assessed in this data for linkage disequilibrium structure using 
Haploview29 . The “solid spine of LD” block definition was used and identified a block between 
SNPs rs3217992 and rs4977756, and haplotypes were calculated in this block. Inclusion of SNPs 
outside this block resulted in a large number of rare and less common haplotypes. Only haplotypes 
with frequency >1% were considered. 
 
Resequencing: 
The coding exons, 3’UTR and all splice sites of TMCO1 were sequenced in twelve cases who were 
homozygous for the risk allele (G) at rs4656461. Primers  are given in Supplementary Table 5. Each 
fragment was amplified by PCR with 0.5U of Hotstart Taq (Qiagen, Doncaster, Australia). 
Following clean-up of PCR products by incubation at 37oC with 2U of Shrimp Alkaline 
Phosphatase (USB, Clevland, OH) and 10U of Exonuclease I (New England Biolabs, MA), 
products were directly sequenced on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, 
Foster City, CA) with BigDye Terminators (Applied Biosystems) according to standard protocols.  
 
Estimates of effect size in replication cohort 
To calculate an unbiased estimate of risk for advanced glaucoma we focused on the replication 
cohort. Taking advanced glaucoma cases (N=334), and the full set of examined replication controls 
(N=936) we fitted rs4977756 and rs4656461 in a logistic regression using R30. Additive effects 
were modelled by coding SNPs as 0/1/2 risk alleles and dominance effects were modelled by 
coding homozygotes as 0 and heterozygotes as 1.  
 
Expression analysis in human ocular tissue 
Ocular tissues from post-mortem human eyes were obtained through the Eye Bank of South 
Australia, according to guidelines of the Southern Adelaide Health Service/Flinders University 
Human Research Ethics Committee. Total RNA was extracted using the RNeasy Mini Kit (Qiagen). 
First strand cDNA was synthesised using the Superscript III reverse transcriptase (Invitrogen, 
Australia) and random hexamers. Human retinal cDNA was synthesised using an oligo-dT primer. 
PCR was performed using the Hot Star Taq polymerase (Qiagen) and gene-specific primers 
(Supplementary Table 5B). For amplification of CDKN2B-AS1 splice variants, PCR was performed 
with gene specific primer Exon 1F (forward) in combination with either Exon 19R, Exon 12-3’R or 
Exon 13R primer (reverse) (Supplementary Table 5C) in the presence of Q Solution (Qiagen). 
Specificity of each amplified products was confirmed by sequencing. Coding exons in each variant 
were determined from alignment with the CDKN2B-AS1 reference sequence NR_003529.3. 
 
Immunohistochemistry in rat ocular tissue 
Tissue sections were deparaffinized in xylene and rinsed in 100% ethanol, before treatment with 
0.5% H2O2 for 30 min to block endogenous peroxidase activity. Antigen retrieval was achieved by 
microwaving the sections in 10 mM citrate buffer (pH 6.0). Tissue sections were then blocked in 
3% normal horse serum/ phosphate buffered saline (PBS) , incubated overnight at room temperature 
in primary antibody, followed by consecutive incubations with biotinylated secondary antibody 
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(Vector, Burlingame, CA) and streptavidin-peroxidase conjugate (Pierce, Rockford, IL). Color 
development was achieved with NovaRED (Vector). Sections were counterstained with 
hematoxylin, dehydrated and mounted. Specificity of antibody staining was confirmed by 
incubating adjacent sections with mouse IgG1 isotype control (BD Pharmingen) or normal rabbit 
serum for the monoclonal antibody and polyclonal rabbit antibodies, respectively. Primary 
antibodies used: anti-mouse CDKN2A (Abcam, clone 2D9A12, 1:1000), CDKN2B (Cell Signaling 
Technology, #4822, 1:1000), anti-rabbit TMCO1 (Aviva Systems Biology, ARP49429_P050, 1:500 
to 1:1000). 
 
For Western blotting to confirm specificity of the TMCO1 antibody, samples from rat liver, brain, 
retina and optic nerve were sonicated in freshly prepared 20mM Tris/HCl buffer (pH 7.4) 
containing 2mM EDTA, 0.5mM EGTA, the protease inhibitors phenylmethyl-sulphonyl fluoride 
(0.1mM), leupeptin (50 μg/ml) and aprotinin (50 μg/ml) plus a phosphatase inhibitor cocktail. An 
equal volume of sample buffer (62.5 mM Tris/HCl, pH 7.4, 4% SDS, 10% glycerol, 10% β-
mercaptoethanol and 0.002% bromophenol blue) was added and samples were boiled for 3 min. 
Samples were size fractionated by SDS-PAGE and transferred onto PVDF membrane. Blot was  
blocked with 5% skimmed milk/Tris buffered saline containing 0.1% Tween 20, probed with 
antibodies to actin or TMCO1 followed by appropriate secondary antibodies conjugated to biotin, 
and then streptavidin-peroxidase conjugate. Blot was developed with a 0.016% solution of 3-amino-
9-ethylcarbazole in 50 mM sodium acetate (pH 5) containing 0.05% Tween-20 and 0.03% H2O2. 
 
Evaluation of gene expression levels in a rat model of glaucoma 
Sprague-Dawley rats were anaesthetised with an intraperitoneal injection of 100 mg/kg ketamine 
and 10 mg/kg xylazine and local anesthetic drops applied to the eye. Ocular hypertension was 
induced in the right eye of each animal by laser photocoagulation of the trabecular meshwork as 
previously described13. IOPs were measured in both eyes at baseline, 8h, day 1, 3 and 7 using a 
rebound tonometer calibrated for use in rats. All rats were killed by transcardial perfusion with 
physiological saline under deep anaesthesia. The retinas were dissected for RT-PCR, while the 
chiasm from each rat was taken for immunohistochemistry to verify that the procedure had induced 
an appropriate injury response using the same method detailed above. Total RNA was isolated from 
each retina and first strand cDNA synthesised from 2 μg DNase-treated RNA. Duplicate real-time 
PCR reactions were carried out using the cDNA equivalent of 20 ng total RNA for each sample in a 
total volume of 25 μl containing 1 × SYBR Green PCR master mix (BioRad), in an IQ5 icycler 
(Bio-Rad)..Primer sets used are detailed in Supplementary Table 5. After the final cycle of the PCR, 
primer specificity was checked by the dissociation (melting) curve method. The relative expression 
in each sample was calculated using Gapdh as reference mRNA as previously described31. 
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